Lipid microparticle growth factor formulations

• US 9,480,649 B2
• Filed: 10/23/2007
• Issued: 11/01/2016
• Est. Priority Date: 10/23/2006
• Status: Expired due to Fees

• Current Assignee: Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH, Healthpartners Research Foundation (Health Partners Institute For Education & Research)
• Original Assignee: Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH, Healthpartners Research Foundation (Health Partners Institute For Education & Research)
• Inventors: Hansom, Leah R., Frey, William H. II, Hoekman, John D., Pohl, Jens
• Primary Examiner(s): BORGEEST, CHRISTINA M
• Application Number:
  US12/446,884
• Publication Number:
  US 20100074959A1
• Time in Patent Office: 3,297 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is directed to novel formulations and methods for the improved delivery and administration of hydrophobic therapeutic compounds that are substantially insoluble and/or susceptible to precipitation in aqueous solution at physiological pH, including, e.g., growth and differentiation factor-5 and related proteins. Many therapeutic compounds are hydrophobic at physiological pH levels.

Claims

1. An aqueous colloidal lipid microparticle (LMP) pharmaceutical composition comprising water, a therapeutic compound in aqueous media at non-physiological pH, at least one lipid carrier, at least one emulsifying agent, and at least one excipient in an amount to allow titration of the pharmaceutical composition to, and maintain at, physiological pH, wherein the pharmaceutical composition is more soluble and less susceptible to precipitation in aqueous solution at physiological pH than the therapeutic compound, wherein said therapeutic compound comprises at least one hydrophobic GDF-5 related protein which is a naturally occurring or artificially created protein which comprises a cystine-knot-domain with an amino acid identity of at least 70% to the 102 aa cystine-knot-domain of human GDF-5 (amino acids 400-501 of SEQ ID NO:

2), wherein the lipid carrier is an oil, and wherein the concentration of the lipid carrier ranges from 5-50 mg/ml.

2. The pharmaceutical composition according to claim 1, wherein the physiologically acceptable pH is within the range of 4 to 8.5.

3. The pharmaceutical composition according to claim 1, wherein the physiologically acceptable pH range is 5 to 7.5.

4. The pharmaceutical composition according to claim 1 wherein the lipid microparticles are lipid nanospheres.

5. The pharmaceutical composition according to claim 1, wherein the therapeutic compound further comprises at least one protein selected from the group consisting of growth factors, neurotrophins, hedgehog proteins, proteins of the TGF-family, antibodies, hormones, enzymes, membrane enzymes, lipoproteins and receptors.

6. The pharmaceutical composition according to claim 1, wherein the GDF-5 related protein is selected from the group consisting of human full-length GDF-5 (SEQ ID NO:

2), human full length GDF-5 lacking the signal peptide (amino acids 28 to 501 of SEQ ID NO;

     2), human mature GDF-5 (SEQ ID NO;

4 and amino acids 382 to 501 of SEQ ID NO;

     1), human mature recombinant GDF-5 (amino acids 383 to 501 of SEQ ID NO;

     2), a protein comprising the cystine-knot region of human GDF-5 (SEQ ID NO;

7 and amino acids 400 to 501 of SEQ ID NO;

2), human mature monomeric GDF-5 (SEQ ID NO;

     3).

7. The pharmaceutical composition according to claim 1, wherein the therapeutic compound further comprises one or more substances selected from the group consisting of peptide-based drugs, oils, phospholipids, antioxidants, anti-inflammatory compounds, bioflavonoids, polyphenols, vitamins, glycolipids, porphyrins, antibiotics, antivirals, antidepressants, anxiolytics, antipsychotics, chemotherapeutic compounds, myricetin, estrogen, progesterone, testosterone, ceramide trihexosidase, neutral sphingomyelinase, and neutraceuticals.

8. The pharmaceutical composition according to claim 1, wherein the lipid carrier is a synthetic oil or a plant oil selected from the group consisting of olive oil, soybean oil, cottonseed oil, soybean oil, sesame oil, sunflower oil, safflower oil, avocado oil, peanut oil, walnut oil, almond oil and hazelnut oil.

9. The pharmaceutical composition according to claim 1, wherein the emulsifying agent is selected from the group consisting of phospholipids, distilled monoglycerides, diglycerides, acetic acid esters of monoglycerides, organic acid esters of monoglycerides, sorbitan esters of fatty acids, propylene glycol esters of fatty acids and polyglycerol esters of fatty esters.

10. The pharmaceutical composition according to claim 9, wherein the phospholipid is selected from the group consisting of phosphatidylserine, phosphatidylcholine and phosphatidyl-ethanolamine.

11. The pharmaceutical composition according to claim 1, wherein the at least one excipient allowing titration of the pharmaceutical composition to, and maintaining at, physiological pH comprises a) an acid or base substance in sufficient quantity to allow titration of the pharmaceutical composition to the desired physiological pH;

and/or b) a buffer in sufficient quantity to allow titration of the pharmaceutical composition to the desired physiological pH and maintain the desired physiological pH.

12. The pharmaceutical composition according to claim 1, further comprising at least one antioxidant.

13. The pharmaceutical composition according to claim 12, wherein the antioxidant is selected from the group consisting of Vitamin E, Vitamin C, and bioflavonoid compounds.

14. The pharmaceutical composition according to claim 1, further comprising at least one odorant.

15. The pharmaceutical composition according to claim 14, wherein the odorant is selected from the group consisting of adenylate cyclase, guanylate cyclase, octyl isovalerate, cetralva, citronellol, amylcinnamaldehyde, CIS-jasmine, jasmal and musk 89.

16. An aqueous colloidal lipid microparticle (LMP) pharmaceutical composition comprising a therapeutic compound, a lipid carrier, and an emulsifying agent, wherein said therapeutic compound comprises at least one hydrophobic GDF-5 related protein which is a naturally occurring or artificially created protein which comprises a cystine-knot-domain with an amino acid identity of at least 70% to the 102 aa cystine-knot-domain of human GDF-5 (amino acids 400-501 of SEQ ID NO:

2), wherein the lipid carrier is an oil, wherein the concentration of the lipid carrier ranges from 5-50 mg/ml and wherein said pharmaceutical composition comprises lipid microparticles with a size between 0.2 and 100 μ

m.

17. The pharmaceutical composition according to claim 16, further comprising at least one excipient in an amount to allow titration of the pharmaceutical composition to, and maintain at, physiological pH.

18. The pharmaceutical composition according to claim 17, wherein the at least one excipient allowing titration of the pharmaceutical composition to, and maintaining at, physiological pH comprises a) an acid or base substance in sufficient quantity to allow titration of the pharmaceutical composition to the desired physiological pH;

and/or b) a buffer in sufficient quantity to allow titration of the pharmaceutical composition to the desired physiological pH and maintain the desired physiological pH.

19. The pharmaceutical composition according to claim 17, wherein the physiologically acceptable pH is within the range of 4 to 8.5.

20. The pharmaceutical composition according to claim 19, wherein the physiologically acceptable pH range is 5 to 7.5.

21. The pharmaceutical composition according to claim 16, wherein the lipid microparticles are lipid nanospheres.

22. The pharmaceutical composition according to claim 16, wherein the therapeutic compound further comprises at least one protein selected from the group consisting of growth factors, neurotrophins, hedgehog proteins, proteins of the TGF-family, antibodies, hormones, enzymes, membrane enzymes, lipoproteins and receptors.

23. The pharmaceutical composition according to claim 16, wherein the GDF-5 related protein is selected from the group consisting of human full-length GDF-5 (SEQ ID NO:

2), human full length GDF-5 lacking the signal peptide (amino acids 28 to 501 of SEQ ID NO;

     2), human mature GDF-5 (SEQ ID NO;

4 and amino acids 382 to 501 of SEQ ID NO;

     1), human mature recombinant GDF-5 (amino acids 383 to 501 of SEQ ID NO;

     2), a protein comprising the cystine-knot region of human GDF-5 (SEQ ID NO;

7 and amino acids 400 to 501 of SEQ ID NO;

2), human mature monomeric GDF-5 (SEQ ID NO;

     3).

24. The pharmaceutical composition according to claim 16, wherein the therapeutic compound further comprises one or more substances selected from the group consisting of peptide-based drugs, oils, phospholipids, antioxidants, anti-inflammatory compounds, bioflavonoids, polyphenols, vitamins, glycolipids, porphyrins, antibiotics, antivirals, antidepressants, anxiolytics, antipsychotics, chemotherapeutic compounds, myricetin, estrogen, progesterone, testosterone, ceramide trihexosidase, neutral sphingomyelinase, and neutraceuticals.

25. The pharmaceutical composition according to claim 16, wherein the lipid carrier is a synthetic oil or a plant oil selected from the group consisting of olive oil, soybean oil, cottonseed oil, soybean oil, sesame oil, sunflower oil, safflower oil, avocado oil, peanut oil, walnut oil, almond oil and hazelnut oil.

26. The pharmaceutical composition according to claim 16, wherein the emulsifying agent is selected from the group consisting of phospholipids, distilled monoglycerides, diglycerides, acetic acid esters of monoglycerides, organic acid esters of monoglycerides, sorbitan esters of fatty acids, propylene glycol esters of fatty acids and polyglycerol esters of fatty esters.

27. The pharmaceutical composition according to claim 26, wherein the phospholipid is selected from the group consisting of phosphatidylserine, phosphatidylcholine and phosphatidyl-ethanolamine.

28. The pharmaceutical composition according to claim 16, further comprising at least one antioxidant.

29. The pharmaceutical composition according to claim 28, wherein the antioxidant is selected from the group consisting of Vitamin E, Vitamin C, and bioflavonoid compounds.

30. The pharmaceutical composition according to claim 16, further comprising at least one odorant.

31. The pharmaceutical composition according to claim 30, wherein the odorant is selected from the group consisting of adenylate cyclase, guanylate cyclase, octyl isovalerate, cetralva, citronellol, amylcinnamaldehyde, CIS-jasmine, jasmal and musk 89.

32. The pharmaceutical composition according to claim 16, wherein the concentration of the lipid carrier ranges from 16 to 30 mg/ml.

33. The pharmaceutical composition according to claim 16, wherein the concentration of the emulsifying agent ranges from 16 to 30 mg/ml.

34. An aqueous colloidal lipid microparticle (LMP) pharmaceutical composition comprising a therapeutic compound, a lipid carrier, and an emulsifying agent, wherein said therapeutic compound comprises at least one hydrophobic GDF-5 related protein which is a naturally occurring or artificially created protein which comprises a cystine-knot-domain with an amino acid identity of at least 70% to the 102 aa cystine-knot-domain of human GDF-5 (amino acids 400-501 of SEQ ID NO:

2), wherein the lipid carrier is an oil, and wherein the concentration of the lipid carrier ranges from 16 to 30 mg/ml.

35. The pharmaceutical composition according to claim 34, further comprising at least one excipient in an amount to allow titration of the pharmaceutical composition to, and maintain at, physiological pH, wherein the pharmaceutical composition is more soluble and less susceptible to precipitation in aqueous solution at physiological pH than the therapeutic compound.

36. The pharmaceutical composition according to claim 35, wherein the at least one excipient allowing titration of the pharmaceutical composition to, and maintaining at, physiological pH comprises a) an acid or base substance in sufficient quantity to allow titration of the pharmaceutical composition to the desired physiological pH;

and/or b) a buffer in sufficient quantity to allow titration of the pharmaceutical composition to the desired physiological pH and maintain the desired physiological pH.

37. The pharmaceutical composition according to claim 35, wherein the physiologically acceptable pH is within the range of 4 to 8.5.

38. The pharmaceutical composition according to claim 37, wherein the physiologically acceptable pH range is 5 to 7.5.

39. The pharmaceutical composition according to claim 34, wherein the pharmaceutical composition comprises lipid microparticles which are lipid nanospheres.

40. The pharmaceutical composition according to claim 34, wherein the therapeutic compound further comprises at least one protein selected from the group consisting of growth factors, neurotrophins, hedgehog proteins, proteins of the TGF-family, antibodies, hormones, enzymes, membrane enzymes, lipoproteins and receptors.

41. The pharmaceutical composition according to claim 34, wherein the GDF-5 related protein is selected from the group consisting of human full-length GDF-5 (SEQ ID NO:

2), human full length GDF-5 lacking the signal peptide (amino acids 28 to 501 of SEQ ID NO;

     2), human mature GDF-5 (SEQ ID NO;

4 and amino acids 382 to 501 of SEQ ID NO;

     1), human mature recombinant GDF-5 (amino acids 383 to 501 of SEQ ID NO;

     2), a protein comprising the cystine-knot region of human GDF-5 (SEQ ID NO;

7 and amino acids 400 to 501 of SEQ ID NO;

2), human mature monomeric GDF-5 (SEQ ID NO;

     3).

42. The pharmaceutical composition according to claim 34, wherein the therapeutic compound further comprises one or more substances selected from the group consisting of peptide-based drugs, oils, phospholipids, antioxidants, anti-inflammatory compounds, bioflavonoids, polyphenols, vitamins, glycolipids, porphyrins, antibiotics, antivirals, antidepressants, anxiolytics, antipsychotics, chemotherapeutic compounds, myricetin, estrogen, progesterone, testosterone, ceramide trihexosidase, neutral sphingomyelinase, and neutraceuticals.

43. The pharmaceutical composition according to claim 34, wherein the lipid carrier is a synthetic oil or a plant oil selected from the group consisting of olive oil, soybean oil, cottonseed oil, soybean oil, sesame oil, sunflower oil, safflower oil, avocado oil, peanut oil, walnut oil, almond oil and hazelnut oil.

44. The pharmaceutical composition according to claim 34, wherein the emulsifying agent is selected from the group consisting of phospholipids, distilled monoglycerides, diglycerides, acetic acid esters of monoglycerides, organic acid esters of monoglycerides, sorbitan esters of fatty acids, propylene glycol esters of fatty acids and polyglycerol esters of fatty esters.

45. The pharmaceutical composition according to claim 44, wherein the phospholipid is selected from the group consisting of phosphatidylserine, phosphatidylcholine and phosphatidyl-ethanolamine.

46. The pharmaceutical composition according to claim 34, further comprising at least one antioxidant.

47. The pharmaceutical composition according to claim 46, wherein the antioxidant is selected from the group consisting of Vitamin E, Vitamin C, and bioflavonoid compounds.

48. The pharmaceutical composition according to claim 34, further comprising at least one odorant.

49. The pharmaceutical composition according to claim 48, wherein the odorant is selected from the group consisting of adenylate cyclase, guanylate cyclase, octyl isovalerate, cetralva, citronellol, amylcinnamaldehyde, CIS-jasmine, jasmal and musk 89.

50. The pharmaceutical composition according to claim 34, wherein the concentration of the emulsifying agent ranges from 16 to 30 mg/ml.

51. An aqueous colloidal lipid microparticle (LMP) pharmaceutical composition comprising a therapeutic compound, a lipid carrier, and an emulsifying agent, wherein said therapeutic compound comprises at least one hydrophobic GDF-5 related protein which is a naturally occurring or artificially created protein which comprises a cystine-knot-domain with an amino acid identity of at least 70% to the 102 aa cystine-knot-domain of human GDF-5 (amino acids 400-501 of SEQ ID NO:

2), wherein the lipid carrier is an oil, wherein the concentration of the lipid carrier ranges from 5-50 mg/ml and, wherein the concentration of the emulsifying agent ranges from 16 to 30 mg/ml.

52. The pharmaceutical composition according to claim 51, further comprising at least one excipient in an amount to allow titration of the pharmaceutical composition to, and maintain at, physiological pH.

53. The pharmaceutical composition according to claim 52, wherein the at least one excipient allowing titration of the pharmaceutical composition to, and maintaining at, physiological pH comprises a) an acid or base substance in sufficient quantity to allow titration of the pharmaceutical composition to the desired physiological pH;

and/or b) a buffer in sufficient quantity to allow titration of the pharmaceutical composition to the desired physiological pH and maintain the desired physiological pH.

54. The pharmaceutical composition according to claim 52, wherein the physiologically acceptable pH is within the range of 4 to 8.5.

55. The pharmaceutical composition according to claim 54, wherein the physiologically acceptable pH range is 5 to 7.5.

56. The pharmaceutical composition according to claim 51, wherein the pharmaceutical composition comprises lipid microparticles which are lipid nanospheres.

57. The pharmaceutical composition according to claim 51, wherein the therapeutic compound further comprises at least one protein selected from the group consisting of growth factors, neurotrophins, hedgehog proteins, proteins of the TGF-family, antibodies, hormones, enzymes, membrane enzymes, lipoproteins and receptors.

58. The pharmaceutical composition according to claim 51, wherein the GDF-5 related protein is selected from the group consisting of human full-length GDF-5 (SEQ ID NO:

2), human full length GDF-5 lacking the signal peptide (amino acids 28 to 501 of SEQ ID NO;

     2), human mature GDF-5 (SEQ ID NO;

4 and amino acids 382 to 501 of SEQ ID NO;

     1), human mature recombinant GDF-5 (amino acids 383 to 501 of SEQ ID NO;

     2), a protein comprising the cystine-knot region of human GDF-5 (SEQ ID NO;

7 and amino acids 400 to 501 of SEQ ID NO;

2), human mature monomeric GDF-5 (SEQ ID NO;

     3).

59. The pharmaceutical composition according to claim 51, wherein the therapeutic compound further comprises one or more substances selected from the group consisting of peptide-based drugs, oils, phospholipids, antioxidants, anti-inflammatory compounds, bioflavonoids, polyphenols, vitamins, glycolipids, porphyrins, antibiotics, antivirals, antidepressants, anxiolytics, antipsychotics, chemotherapeutic compounds, myricetin, estrogen, progesterone, testosterone, ceramide trihexosidase, neutral sphingomyelinase, and neutraceuticals.

60. The pharmaceutical composition according to claim 51, wherein the lipid carrier is a synthetic oil or a plant oil selected from the group consisting of olive oil, soybean oil, cottonseed oil, soybean oil, sesame oil, sunflower oil, safflower oil, avocado oil, peanut oil, walnut oil, almond oil and hazelnut oil.

61. The pharmaceutical composition according to claim 51, wherein the emulsifying agent is selected from the group consisting of phospholipids, distilled monoglycerides, diglycerides, acetic acid esters of monoglycerides, organic acid esters of monoglycerides, sorbitan esters of fatty acids, propylene glycol esters of fatty acids and polyglycerol esters of fatty esters.

62. The pharmaceutical composition according to claim 61, wherein the phospholipid is selected from the group consisting of phosphatidylserine, phosphatidylcholine and phosphatidyl-ethanolamine.

63. The pharmaceutical composition according to claim 51, further comprising at least one antioxidant.

64. The pharmaceutical composition according to claim 63, wherein the antioxidant is selected from the group consisting of Vitamin E, Vitamin C, and bioflavonoid compounds.

65. The pharmaceutical composition according to claim 51, further comprising at least one odorant.

66. The pharmaceutical composition according to claim 65, wherein the odorant is selected from the group consisting of adenylate cyclase, guanylate cyclase, octyl isovalerate, cetralva, citronellol, amylcinnamaldehyde, CIS-jasmine, jasmal and musk 89.